European Chief Operating Officer,
Jeremy Haigh is responsible for Amgen’s Research & Development sites across Europe, the Middle East and Africa (EMEA), and for Global Development staff located in the region. He is a director of Amgen Limited, BioVex Limited, and the recently acquired Amgen Research (Munich) GmbH, a member of the Global Development Senior Leadership Team and of Amgen’s European Management Committee. He is based at the European R&D headquarters in the UK.
Jeremy has spent over 25 years in the bioscience sector in a variety of clinical research, development, operational and leadership roles. He has experienced both traditional pharmaceutical and biotechnology environments at Merck (1988 – 1995) and at Amgen (since 1996) where latterly he has been deeply involved in the organizational development, governance and asset integration associated with a rapidly expanding company. He has a long standing interest in novel approaches to neurological disease, and has been closely associated with the development and registration of a number of new molecular entities in different therapeutic areas.
Jeremy graduated in pharmacology from the University of Leeds (1982), received a Ph.D. in neuro-pharmacology (1985) and completed a post-doctoral research fellowship in clinical pharmacology. He has held university teaching and examining positions, and authored over 30 peer reviewed publications. Jeremy is a Director of the BioIndustry Association (BIA) and a member of The Association of the British Pharmaceutical Industry (ABPI) Innovation Board. He represents Amgen at the EFPIA Research Directors Group and attends various UK government-led committees.